Project Syndicate op-ed: Insulin Belongs to the World

In an op-ed published by Project Syndicate, Access to Medicine Foundation CEO Jayasree K. Iyer argues that governments and pharmaceutical companies must do their part to increase access to insulin in low- and middle-income countries – including not just older forms of human insulin, but also the innovative analog insulins which are increasingly becoming the preferred choice of both diabetes patients and doctors.

When insulin was discovered 101 years ago, scientists involved said they wanted to make insulin as widely available as possible because “it belongs to the world.” But as Jayasree points out, this ambition will not be fulfilled until every person who needs insulin – whether they have Type 1 or Type 2 diabetes – is assured reliable access to an affordable supply of the treatments that suit them best.

To reach this goal, chronic problems in the insulin market must be addressed, as explored in the article.

Project Syndicate, known as "the world's opinion page", is a New York-based international media organisation that publishes commentary and analysis on a variety of important topics, and also syndicates these opinion pieces to print publications around the world.

Foundation to deepen its work moving pharma companies on access to diabetes care

Each year, more than 100,000 children and young adults are diagnosed with type 1 diabetes. Although the products that can keep them alive do exist, these are often out of reach for people living in low- and middle-income countries. In 2022, the Foundation will assess the best solutions for pharma companies to build sustainable and equitable access to diabetes care.

Project Syndicate op-ed: Insulin Belongs to the World

Explore further

Biosimilar Access: Is The Industry Overlooking Critical Markets?

AMR.Solutions: Fireside Chat about AMR Benchmark Report

Foundation to deepen its work moving pharma companies on access to diabetes care

Get in touch

Kelly DeBaene